Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17457570 | 0.81 | MAPT (0.35) | MAPTKMT2APTGDR2MEN1GAA | |
| SCHEMBL17457571 | 0.80 | HTR6 (0.36) | MAPTKMT2APTGDR2MEN1GAA | |
| SCHEMBL16100251 | 0.79 | HTR6 (0.38) | MAPTKMT2APTGDR2MEN1GAA | |
| SCHEMBL16120066 | 0.72 | HTR6 (0.41) | HTR6F2ALDH1A1 | |
| SCHEMBL17457576 | 0.72 | HTR6 (0.45) | HTR6 | |
| SCHEMBL16100519 | 0.65 | PTGDR2 (0.35) | KMT2APTGDR2MEN1HTR6F2 | |
| SCHEMBL16119961 | 0.64 | HRH1 (0.38) | KMT2APTGDR2MEN1HTR6POLB | |
| SCHEMBL16100818 | 0.64 | HRH1 (0.41) | MAPTKMT2APTGDR2MEN1HTR6 | |
| SCHEMBL16102368 | 0.63 | HTR6 (0.43) | MAPTKMT2AMEN1HTR6SMN1; SMN2 | |
| SCHEMBL9948843 | 0.60 | HTR6 (0.48) | MAPTKMT2APTGDR2MEN1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9765035-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | MAPT 1345/4885KMT2A 76/4885PTGDR2 4024/4885 |
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | MAPT 1345/4885KMT2A 76/4885PTGDR2 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.